Cyclacel Phar Pr Financials
Cyclacel Phar Pr (CYCCP) reported $747K in revenue for fiscal year 2025, up 1637.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not product revenue, is still carrying the business while a much smaller R&D program reshapes costs.
The move from negative equity and tight liquidity to positive equity and 4.7x current coverage looks like healing, but it came alongside-$4.8M of operating cash flow and only$747K of revenue. That combination implies the balance-sheet improvement was driven by recapitalization and liability reduction rather than an operating model that funds itself.
Reported profit and operating reality are still far apart: FY2025 net income was
The spending mix has flipped. R&D fell from
Financial Health Signals
Cyclacel Phar Pr does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Cyclacel Phar Pr scores -76.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($9.6M) relative to total liabilities ($1.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cyclacel Phar Pr passes 3 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Cyclacel Phar Pr used $1.59 of operating cash (-$4.8M OCF vs $3.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely.
Cyclacel Phar Pr reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Cyclacel Phar Pr generated $747K in revenue in fiscal year 2025. This represents an increase of 1637.2% from the prior year.
Cyclacel Phar Pr's EBITDA was -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 29.8% from the prior year.
Cyclacel Phar Pr reported $3.0M in net income in fiscal year 2025. This represents a decrease of 73.3% from the prior year.
Cyclacel Phar Pr earned -$6.45 per diluted share (EPS) in fiscal year 2025. This represents an increase of 98.7% from the prior year.
Cash & Balance Sheet
Cyclacel Phar Pr held $3.5M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Cyclacel Phar Pr's ROE was 43.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Cyclacel Phar Pr invested $848K in research and development in fiscal year 2025. This represents a decrease of 87.3% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
CYCCP Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $747K+1637.2% | $43K-89.8% | $420K | $0 | $0 | $0 | N/A | $150K | $0-100.0% | $843K-56.6% | $1.9M+12.1% | $1.7M+60.0% | $1.1M+1471.0% | $69K-90.1% | $699K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $360K |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $339K |
| R&D Expenses | N/A | $848K-87.3% | $6.7M-65.3% | $19.2M-5.5% | $20.3M+35.8% | $14.9M+213.7% | $4.8M+2.2% | $4.7M+7.6% | $4.3M+2.1% | $4.2M-55.3% | $9.5M-23.5% | $12.4M-32.3% | $18.3M+62.1% | $11.3M+71.1% | $6.6M-28.4% | $9.2M |
| SG&A Expenses | N/A | $7.7M+43.1% | $5.4M-19.7% | $6.7M-9.0% | $7.4M-1.1% | $7.5M+27.0% | $5.9M+17.0% | $5.0M-6.5% | $5.4M+2.2% | $5.3M-4.7% | $5.5M-3.8% | $5.7M-2.7% | $5.9M-24.3% | $7.8M-9.3% | $8.6M+31.2% | $6.5M |
| Operating Income | N/A | -$8.4M+29.8% | -$12.0M+52.8% | -$25.5M+8.0% | -$27.7M-23.5% | -$22.4M-110.5% | -$10.6M-9.9% | -$9.7M-1.4% | -$9.5M-0.6% | -$9.5M+32.9% | -$14.2M+12.5% | -$16.2M+27.9% | -$22.4M-24.8% | -$18.0M-19.0% | -$15.1M+4.1% | -$15.7M |
| Interest Expense | N/A | $62K+416.7% | $12K | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | $7K+100.9% | -$782K+73.9% | -$3.0M+36.5% | -$4.7M-26.5% | -$3.7M-201.6% | -$1.2M+4.6% | -$1.3M+3.1% | -$1.3M-34.6% | -$993K+49.9% | -$2.0M+7.5% | -$2.1M+33.9% | -$3.2M-94.2% | -$1.7M-23.6% | -$1.4M-139.1% | -$565K |
| Net Income | N/A | $3.0M-73.3% | $11.2M-50.3% | $22.6M+206.4% | -$21.2M-14.9% | -$18.5M-118.6% | -$8.4M-7.9% | -$7.8M-7.4% | -$7.3M+2.4% | -$7.5M+36.6% | -$11.8M+17.8% | -$14.3M+26.0% | -$19.4M-90.9% | -$10.2M+23.0% | -$13.2M+13.5% | -$15.2M |
| EPS (Diluted) | — | -$6.45+98.7% | -$502.46-7727.5% | -$6.42 | -$27.24 | -$2.09 | -$3.42 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CYCCP Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $8.2M+99.9% | $4.1M-53.5% | $8.8M-68.6% | $28.1M-35.0% | $43.1M+17.2% | $36.8M+140.4% | $15.3M-22.8% | $19.8M-23.8% | $26.0M+32.3% | $19.7M-20.6% | $24.8M-15.7% | $29.4M-17.3% | $35.5M+83.5% | $19.4M-25.6% | $26.0M |
| Current Assets | $6.3M+70.3% | $3.7M-50.6% | $7.4M-69.5% | $24.4M-40.4% | $40.9M+15.4% | $35.5M+153.0% | $14.0M-29.2% | $19.8M-23.8% | $26.0M+32.4% | $19.6M-20.1% | $24.6M-15.3% | $29.0M-17.6% | $35.2M+86.4% | $18.9M-26.9% | $25.8M |
| Cash & Equivalents | $3.5M+11.7% | $3.1M-7.1% | $3.4M-81.6% | $18.3M-49.8% | $36.6M+9.4% | $33.4M+181.1% | $11.9M-32.1% | $17.5M-26.8% | $23.9M+44.7% | $16.5M-19.2% | $20.4M-15.5% | $24.2M-22.3% | $31.1M+89.8% | $16.4M-32.9% | $24.4M |
| Inventory | $1.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $1.3M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $10K | N/A | N/A | N/A | N/A | $116K |
| Goodwill | $1.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $1.3M-78.6% | $6.3M-23.5% | $8.2M+7.6% | $7.6M+39.9% | $5.4M+53.6% | $3.5M-1.9% | $3.6M-20.7% | $4.6M+7.4% | $4.2M-21.4% | $5.4M-9.1% | $5.9M-23.0% | $7.7M+2.7% | $7.5M-19.7% | $9.3M+43.7% | $6.5M |
| Current Liabilities | $1.3M-78.7% | $6.3M-23.2% | $8.2M+8.7% | $7.5M+38.8% | $5.4M+117.7% | $2.5M+2.7% | $2.4M-45.6% | $4.5M+8.2% | $4.1M-21.8% | $5.3M-8.6% | $5.8M-23.2% | $7.5M+3.3% | $7.3M-22.3% | $9.3M+43.7% | $6.5M |
| Total Equity | $6.8M+414.7% | -$2.2M-458.2% | $607K-96.2% | $15.9M-57.7% | $37.7M+13.3% | $33.3M+184.3% | $11.7M-23.4% | $15.3M-29.8% | $21.8M+52.5% | $14.3M-24.2% | $18.8M-13.2% | $21.7M-22.6% | $28.0M+179.7% | $10.0M-48.6% | $19.5M |
| Retained Earnings | -$454.4M-3.4% | -$439.5M-2.6% | -$428.3M-5.6% | -$405.7M-5.5% | -$384.5M-5.0% | -$366.1M-2.4% | -$357.6M-2.2% | -$349.8M-2.1% | -$342.5M-2.2% | -$335.0M-3.7% | -$323.2M-4.6% | -$308.8M-6.7% | -$289.4M-7.1% | -$270.3M-5.1% | -$257.1M |
Not reported in any period shown, so not listed: Long-Term Debt.
CYCCP Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.8M | -$4.8M+40.3% | -$8.0M+50.4% | -$16.1M+22.6% | -$20.8M-12.3% | -$18.5M-133.7% | -$7.9M+16.0% | -$9.4M-41.0% | -$6.7M+10.4% | -$7.5M+25.8% | -$10.1M+30.3% | -$14.5M+22.7% | -$18.7M-2.8% | -$18.2M-51.1% | -$12.0M+13.8% | -$14.0M |
| Capital Expenditures | N/A | N/A | N/A | $6K-14.3% | $7K-74.1% | $27K-71.9% | $96K+860.0% | $10K-74.4% | $39K+200.0% | $13K+333.3% | $3K-91.2% | $34K-89.0% | $309K+48.6% | $208K+1633.3% | $12K+100.0% | $6K |
| Free Cash Flow | N/A | N/A | N/A | -$16.1M+22.6% | -$20.8M-12.2% | -$18.6M-131.2% | -$8.0M+15.1% | -$9.5M-40.3% | -$6.7M+10.0% | -$7.5M+25.7% | -$10.1M+30.4% | -$14.5M+23.8% | -$19.0M-3.3% | -$18.4M-52.7% | -$12.1M+13.8% | -$14.0M |
| Investing Cash Flow | N/A | N/A | N/A | -$6K+14.3% | -$7K+74.1% | -$27K+71.9% | -$96K-442.9% | $28K+171.8% | -$39K-200.0% | -$13K | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $1.7M | $5.3M-32.7% | $7.8M+822.4% | $848K-71.7% | $3.0M-86.2% | $21.7M-26.3% | $29.5M+666.7% | $3.8M+797.0% | $429K-97.1% | $14.7M | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CYCCP Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 48.5% |
| Operating Margin | -1128.1% | -27916.3% | -6060.2% | N/A | N/A | N/A | N/A | -6365.3% | N/A | -1678.5% | -831.8% | -1293.9% | -1658.1% | -21888.4% | -2252.9% |
| Net Margin | 401.3% | 26074.4% | 5370.2% | N/A | N/A | N/A | N/A | -4858.7% | N/A | -1398.7% | -737.8% | -1118.0% | -936.6% | -19110.1% | -2180.7% |
| Return on Equity | 43.8% | N/A | 3715.8%+3848.8pp | -133.0%-84.0pp | -49.0%-23.6pp | -25.4%+41.5pp | -66.9%-19.2pp | -47.7%-13.4pp | -34.3%+48.3pp | -82.6%-6.5pp | -76.1%+13.2pp | -89.4%-53.2pp | -36.2%+95.4pp | -131.6%-53.4pp | -78.2% |
| Return on Assets | 36.6%-237.2pp | 273.9%+17.7pp | 256.2%+331.7pp | -75.6%-32.8pp | -42.8%-19.8pp | -22.9%+28.2pp | -51.1%-14.4pp | -36.8%-8.0pp | -28.7%+31.2pp | -60.0%-2.1pp | -57.9%+8.1pp | -66.0%-37.4pp | -28.6%+39.6pp | -68.1%-9.5pp | -58.6% |
| Current Ratio | 4.70+4.1x | 0.59-0.3x | 0.91-2.3x | 3.25-4.3x | 7.56-6.7x | 14.27+8.5x | 5.79+1.3x | 4.45-1.9x | 6.32+2.6x | 3.73-0.5x | 4.27+0.4x | 3.87-1.0x | 4.85+2.8x | 2.02-2.0x | 3.98 |
| Debt-to-Equity | 0.20 | N/A | 13.51+13.0x | 0.48+0.3x | 0.140.0x | 0.11-0.2x | 0.310.0x | 0.30+0.1x | 0.19-0.2x | 0.38+0.1x | 0.310.0x | 0.35+0.1x | 0.27-0.7x | 0.93+0.6x | 0.33 |
| FCF Margin | N/A | N/A | -3837.6% | N/A | N/A | N/A | N/A | -4493.3% | N/A | -1196.0% | -745.6% | -1096.4% | -1698.1% | -17471.0% | -2000.4% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Cyclacel Phar Pr Ranks
Frequently Asked Questions
What is Cyclacel Phar Pr's annual revenue?
Cyclacel Phar Pr (CYCCP) reported $747K in total revenue for fiscal year 2025. This represents a 1637.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cyclacel Phar Pr's revenue growing?
Cyclacel Phar Pr (CYCCP) revenue grew by 1637.2% year-over-year, from $43K to $747K in fiscal year 2025.
Is Cyclacel Phar Pr profitable?
Yes, Cyclacel Phar Pr (CYCCP) reported a net income of $3.0M in fiscal year 2025.
What is Cyclacel Phar Pr's EBITDA?
Cyclacel Phar Pr (CYCCP) had EBITDA of -$8.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Cyclacel Phar Pr's return on equity (ROE)?
Cyclacel Phar Pr (CYCCP) has a return on equity of 43.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Cyclacel Phar Pr's operating cash flow?
Cyclacel Phar Pr (CYCCP) recorded an outflow of $4.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Cyclacel Phar Pr's total assets?
Cyclacel Phar Pr (CYCCP) had $8.2M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Cyclacel Phar Pr spend on research and development?
Cyclacel Phar Pr (CYCCP) invested $848K in research and development during fiscal year 2025.
What is Cyclacel Phar Pr's current ratio?
Cyclacel Phar Pr (CYCCP) had a current ratio of 4.70 as of fiscal year 2025, which is generally considered healthy.
What is Cyclacel Phar Pr's debt-to-equity ratio?
Cyclacel Phar Pr (CYCCP) had a debt-to-equity ratio of 0.20 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Cyclacel Phar Pr's return on assets (ROA)?
Cyclacel Phar Pr (CYCCP) had a return on assets of 36.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Cyclacel Phar Pr's cash runway?
Based on fiscal year 2025 data, Cyclacel Phar Pr (CYCCP) had $3.5M in cash against an annual operating cash burn of $4.8M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Cyclacel Phar Pr's Altman Z-Score?
Cyclacel Phar Pr (CYCCP) has an Altman Z-Score of -76.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cyclacel Phar Pr's Piotroski F-Score?
Cyclacel Phar Pr (CYCCP) has a Piotroski F-Score of 3 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cyclacel Phar Pr's earnings high quality?
For every $1 of reported earnings, Cyclacel Phar Pr (CYCCP) used $1.59 of operating cash (-$4.8M OCF vs $3.0M net income). Earnings that no cash stands behind rest on accounting accruals, which cannot be repeated indefinitely. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cyclacel Phar Pr cover its interest payments?
Cyclacel Phar Pr (CYCCP) reported an operating loss of $8.4M against $62K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.